Skip to main content
Top
Published in: Heart Failure Reviews 1/2020

01-01-2020 | Diuretics

Loop diuretic resistance complicating acute heart failure

Authors: Zachary L. Cox, Jeffrey M. Testani

Published in: Heart Failure Reviews | Issue 1/2020

Login to get access

Abstract

Acute heart failure hospitalizations complicated by diuretic resistance are associated with worse outcomes. Yet, quantification of the frequency and accompanying risk from loop diuretic resistance is limited by the absence of a comprehensive definition with universal clinical application. Herein, we outline limitations of the current metrics used to identify and define diuretic resistance. We discuss the best available methods to identify and prognosticate outcomes in diuretic resistance. We propose a mechanism-based classification system of diuretic resistance by anatomical location as follows: pre-nephron resistance, pre-loop of Henle resistance, loop of Henle resistance, and post-loop of Henle resistance. Within this paradigm, we compare and contrast historical beliefs of resistance mechanisms with current literature specific to patients with heart failure. We recommend a treatment pathway to restore diuretic efficacy with a literature review of the various combination diuretic strategies and ongoing clinical trials that may impact current best practices.
Literature
1.
go back to reference Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW (2007) Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 153:1021–1028PubMed Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW (2007) Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 153:1021–1028PubMed
2.
go back to reference Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63:1123–1133PubMed Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63:1123–1133PubMed
3.
go back to reference Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ (2019) The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:137–155PubMed Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ (2019) The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:137–155PubMed
4.
go back to reference Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM, Myerberg RJ (1991) Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 90:353–359PubMed Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM, Myerberg RJ (1991) Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 90:353–359PubMed
5.
go back to reference Elder A, Japp A, Verghese A (2016) How valuable is physical examination of the cardiovascular system? BMJ. 354:i3309PubMed Elder A, Japp A, Verghese A (2016) How valuable is physical examination of the cardiovascular system? BMJ. 354:i3309PubMed
6.
go back to reference Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, Califf RM, Nohria A (2008) Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail 1:170–177PubMedPubMedCentral Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, Califf RM, Nohria A (2008) Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail 1:170–177PubMedPubMedCentral
7.
go back to reference Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261:884–888PubMed Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261:884–888PubMed
8.
go back to reference Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596PubMedPubMedCentral Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596PubMedPubMedCentral
9.
go back to reference Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51:1268–1274PubMed Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51:1268–1274PubMed
10.
go back to reference Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMed Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMed
12.
go back to reference Testani JM, Kimmel SE, Dries DL, Coca SG (2011) Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4:685–691PubMedPubMedCentral Testani JM, Kimmel SE, Dries DL, Coca SG (2011) Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4:685–691PubMedPubMedCentral
13.
go back to reference Michel A, Martin-Perez M, Ruigomez A, Garcia Rodriguez LA (2016) Incidence and risk factors for severe renal impairment after first diagnosis of heart failure: a cohort and nested case-control study in UK general practice. Int J Cardiol 207:252–257PubMed Michel A, Martin-Perez M, Ruigomez A, Garcia Rodriguez LA (2016) Incidence and risk factors for severe renal impairment after first diagnosis of heart failure: a cohort and nested case-control study in UK general practice. Int J Cardiol 207:252–257PubMed
14.
go back to reference Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMed Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMed
15.
go back to reference Desai AS (2013) Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation. 127:509–516 discussion 516 PubMed Desai AS (2013) Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation. 127:509–516 discussion 516 PubMed
16.
go back to reference Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JP, Marques I, Schroeder-Tanka JM, Keijer JT, Bayes-Genis A, Tijssen JGP, Pinto YM, Kok WE (2018) NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation. 137:1671–1683PubMed Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JP, Marques I, Schroeder-Tanka JM, Keijer JT, Bayes-Genis A, Tijssen JGP, Pinto YM, Kok WE (2018) NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation. 137:1671–1683PubMed
17.
go back to reference Kociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, O’Connor CM, Felker GM, NHLBI Heart Failure Network Steering Committee and Investigators (2013) Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 6:240–245PubMed Kociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, O’Connor CM, Felker GM, NHLBI Heart Failure Network Steering Committee and Investigators (2013) Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 6:240–245PubMed
18.
go back to reference Cooper LB, Mentz RJ, Gallup D, Lala A, DeVore AD, Vader JM, AbouEzzeddine OF, Bart BA, Anstrom KJ, Hernandez AF, Felker GM (2016) Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes. J Card Fail 22:738–742PubMedPubMedCentral Cooper LB, Mentz RJ, Gallup D, Lala A, DeVore AD, Vader JM, AbouEzzeddine OF, Bart BA, Anstrom KJ, Hernandez AF, Felker GM (2016) Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes. J Card Fail 22:738–742PubMedPubMedCentral
19.
go back to reference Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW (2015) Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail 8:741–748PubMedPubMedCentral Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW (2015) Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail 8:741–748PubMedPubMedCentral
20.
go back to reference Miller WL (2016) Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail 9:e002922PubMed Miller WL (2016) Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail 9:e002922PubMed
21.
go back to reference Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M (2002) Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144:31–38PubMed Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M (2002) Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144:31–38PubMed
22.
go back to reference Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE (2011) Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 58:375–382PubMedPubMedCentral Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE (2011) Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 58:375–382PubMedPubMedCentral
23.
go back to reference Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A (2011) Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail 13:1244–1252PubMed Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A (2011) Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail 13:1244–1252PubMed
24.
go back to reference Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH (2014) Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 7:261–270PubMed Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH (2014) Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 7:261–270PubMed
25.
go back to reference Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, Kula A, Chen M, Wilson FP, Darlington A, Bellumkonda L, Jacoby D, Tang WH, Parikh CR (2016) Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail 9:e002370PubMedPubMedCentral Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, Kula A, Chen M, Wilson FP, Darlington A, Bellumkonda L, Jacoby D, Tang WH, Parikh CR (2016) Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail 9:e002370PubMedPubMedCentral
26.
go back to reference Brinkley DM Jr, Burpee LJ, Chaudhry SP, Smallwood JA, Lindenfeld J, Lakdawala NK, Desai AS, Stevenson LW (2018) Spot urine sodium as triage for effective diuretic infusion in an ambulatory heart failure unit. J Card Fail 24:349–354PubMed Brinkley DM Jr, Burpee LJ, Chaudhry SP, Smallwood JA, Lindenfeld J, Lakdawala NK, Desai AS, Stevenson LW (2018) Spot urine sodium as triage for effective diuretic infusion in an ambulatory heart failure unit. J Card Fail 24:349–354PubMed
27.
go back to reference Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, Tang WH (2014) Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail 20:392–399PubMedPubMedCentral Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, Tang WH (2014) Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail 20:392–399PubMedPubMedCentral
28.
go back to reference Verbrugge FH, Nijst P, Dupont M, Penders J, Tang WH, Mullens W (2014) Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ Heart Fail 7:766–772PubMed Verbrugge FH, Nijst P, Dupont M, Penders J, Tang WH, Mullens W (2014) Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ Heart Fail 7:766–772PubMed
29.
go back to reference Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O’Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ (2017) Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF trial. JACC Heart Fail 5:1–13PubMedPubMedCentral Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O’Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ (2017) Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF trial. JACC Heart Fail 5:1–13PubMedPubMedCentral
30.
go back to reference Testani JM, Brisco MA, Kociol RD, Jacoby D, Bellumkonda L, Parikh CR, Coca SG, Tang WH (2015) Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment. Am J Med 128:776–783 e4 PubMedPubMedCentral Testani JM, Brisco MA, Kociol RD, Jacoby D, Bellumkonda L, Parikh CR, Coca SG, Tang WH (2015) Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment. Am J Med 128:776–783 e4 PubMedPubMedCentral
31.
go back to reference Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 118:1433–1441PubMed Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 118:1433–1441PubMed
32.
go back to reference Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM (2007) Patterns of weight change preceding hospitalization for heart failure. Circulation. 116:1549–1554PubMedPubMedCentral Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM (2007) Patterns of weight change preceding hospitalization for heart failure. Circulation. 116:1549–1554PubMedPubMedCentral
33.
go back to reference Patarroyo M, Wehbe E, Hanna M, Taylor DO, Starling RC, Demirjian S, Tang WH (2012) Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol 60:1906–1912PubMed Patarroyo M, Wehbe E, Hanna M, Taylor DO, Starling RC, Demirjian S, Tang WH (2012) Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol 60:1906–1912PubMed
34.
go back to reference Kiernan MS, Stevens SR, Tang WHW, Butler J, Anstrom KJ, Birati EY, Grodin JL, Gupta D, Margulies KB, LaRue S, Davila-Roman VG, Hernandez AF, de Las FL, Investigators NHFCTN (2018) Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis from the NHLBI heart failure network clinical trials. J Card Fail 24:428–438PubMedPubMedCentral Kiernan MS, Stevens SR, Tang WHW, Butler J, Anstrom KJ, Birati EY, Grodin JL, Gupta D, Margulies KB, LaRue S, Davila-Roman VG, Hernandez AF, de Las FL, Investigators NHFCTN (2018) Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis from the NHLBI heart failure network clinical trials. J Card Fail 24:428–438PubMedPubMedCentral
35.
go back to reference Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–1293PubMed Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–1293PubMed
36.
go back to reference Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Perez-Calvo JI, Voors AA (2018) Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol 258:185–191PubMed Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Perez-Calvo JI, Voors AA (2018) Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol 258:185–191PubMed
37.
go back to reference Felker GM, Mentz RJ (2012) Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 59:2145–2153PubMed Felker GM, Mentz RJ (2012) Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 59:2145–2153PubMed
38.
go back to reference Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, O’Connor CM, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM (2015) Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail 3:97–107PubMed Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, O’Connor CM, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM (2015) Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail 3:97–107PubMed
39.
go back to reference Hanberg JS, Tang WHW, Wilson FP, Coca SG, Ahmad T, Brisco MA, Testani JM (2017) An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. Int J Cardiol 241:277–282PubMedPubMedCentral Hanberg JS, Tang WHW, Wilson FP, Coca SG, Ahmad T, Brisco MA, Testani JM (2017) An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. Int J Cardiol 241:277–282PubMedPubMedCentral
40.
go back to reference Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797–805PubMedPubMedCentral Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797–805PubMedPubMedCentral
41.
go back to reference Honda S, Nagai T, Nishimura K, Nakai M, Honda Y, Nakano H, Iwakami N, Sugano Y, Asaumi Y, Aiba T, Noguchi T, Kusano K, Yokoyama H, Ogawa H, Yasuda S, Anzai T, NaDEF Investigators (2018) Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. Int J Cardiol 254:189–194PubMed Honda S, Nagai T, Nishimura K, Nakai M, Honda Y, Nakano H, Iwakami N, Sugano Y, Asaumi Y, Aiba T, Noguchi T, Kusano K, Yokoyama H, Ogawa H, Yasuda S, Anzai T, NaDEF Investigators (2018) Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. Int J Cardiol 254:189–194PubMed
42.
go back to reference Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, Brown NJ, Liu D, Luther JM, McNaughton CD, Self WH, Peng D, Testani JM, Lindenfeld J (2019) Early urine electrolyte patterns in patients with acute heart failure. ESC Heart Fail 6:80–88PubMed Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, Brown NJ, Liu D, Luther JM, McNaughton CD, Self WH, Peng D, Testani JM, Lindenfeld J (2019) Early urine electrolyte patterns in patients with acute heart failure. ESC Heart Fail 6:80–88PubMed
43.
go back to reference Luk A, Groarke JD, Desai AS, Mahmood SS, Gopal DM, Joyce E, Shah SP, Lindenfeld J, Stevenson L, Lakdawala NK (2018) First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. Am Heart J 203:95–100PubMed Luk A, Groarke JD, Desai AS, Mahmood SS, Gopal DM, Joyce E, Shah SP, Lindenfeld J, Stevenson L, Lakdawala NK (2018) First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. Am Heart J 203:95–100PubMed
44.
go back to reference Biegus J, Zymlinski R, Sokolski M, Todd J, Cotter G, Metra M, Jankowska EA, Banasiak W, Ponikowski P (2019) Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail 21:624–633PubMed Biegus J, Zymlinski R, Sokolski M, Todd J, Cotter G, Metra M, Jankowska EA, Banasiak W, Ponikowski P (2019) Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail 21:624–633PubMed
47.
48.
go back to reference Wilcox CS (2002) New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798–805PubMed Wilcox CS (2002) New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13:798–805PubMed
49.
go back to reference Beermann B, Midskov C (1986) Reduced bioavailability and effect of furosemide given with food. Eur J Clin Pharmacol 29:725–727PubMed Beermann B, Midskov C (1986) Reduced bioavailability and effect of furosemide given with food. Eur J Clin Pharmacol 29:725–727PubMed
50.
go back to reference Phakdeekitcharoen B, Boonyawat K (2012) The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study. BMC Nephrol 13:92PubMedPubMedCentral Phakdeekitcharoen B, Boonyawat K (2012) The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study. BMC Nephrol 13:92PubMedPubMedCentral
51.
go back to reference Loon NR, Wilcox CS, Unwin RJ (1989) Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36:682–689PubMed Loon NR, Wilcox CS, Unwin RJ (1989) Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36:682–689PubMed
52.
go back to reference McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF (1996) Effect of food on the absorption of furosemide and bumetanide in man. Br J Clin Pharmacol 42:743–746PubMedPubMedCentral McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF (1996) Effect of food on the absorption of furosemide and bumetanide in man. Br J Clin Pharmacol 42:743–746PubMedPubMedCentral
53.
go back to reference Nakahama H, Orita Y, Yamazaki M, Itoh S, Okuda T, Yamaji A, Miwa Y, Yanase M, Fukuhara Y, Kamada T (1988) Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. Nephron. 49:223–227PubMed Nakahama H, Orita Y, Yamazaki M, Itoh S, Okuda T, Yamaji A, Miwa Y, Yanase M, Fukuhara Y, Kamada T (1988) Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. Nephron. 49:223–227PubMed
54.
go back to reference Bock JS, Gottlieb SS (2010) Cardiorenal syndrome: new perspectives. Circulation. 121:2592–2600PubMed Bock JS, Gottlieb SS (2010) Cardiorenal syndrome: new perspectives. Circulation. 121:2592–2600PubMed
55.
go back to reference Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O’Connor CM, Starling RC, Hernandez AF (2013) Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF. J Am Coll Cardiol 62:1177–1183PubMed Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O’Connor CM, Starling RC, Hernandez AF (2013) Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF. J Am Coll Cardiol 62:1177–1183PubMed
56.
go back to reference Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287:1541–1547PubMed Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287:1541–1547PubMed
57.
go back to reference Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigram MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Davila-Roman VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310:2533–2543PubMedPubMedCentral Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigram MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Davila-Roman VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310:2533–2543PubMedPubMedCentral
58.
go back to reference Packer M, O’Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J, True-AHF Investigators (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 376:1956–1964PubMed Packer M, O’Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J, True-AHF Investigators (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 376:1956–1964PubMed
59.
go back to reference Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, RELAX-AHF Investigators (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 381:29–39PubMed Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, RELAX-AHF Investigators (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 381:29–39PubMed
60.
go back to reference Sharma K, Vaishnav J, Kalathiya R, Hu JR, Miller J, Shah N, Hill T, Sharp M, Tsao A, Alexander KM, Gupta R, Montemayor K, Kovell L, Chasler JE, Lee YJ, Fine DM, Kass DA, Weiss RG, Thiemann DR, Ndumele CE, Schulman SP, Russell SD, Osler Medical Housestaff (2018) Randomized evaluation of heart failure with preserved ejection fraction patients with acute heart failure and dopamine: the ROPA-DOP trial. JACC Heart Fail 6:859–870PubMed Sharma K, Vaishnav J, Kalathiya R, Hu JR, Miller J, Shah N, Hill T, Sharp M, Tsao A, Alexander KM, Gupta R, Montemayor K, Kovell L, Chasler JE, Lee YJ, Fine DM, Kass DA, Weiss RG, Thiemann DR, Ndumele CE, Schulman SP, Russell SD, Osler Medical Housestaff (2018) Randomized evaluation of heart failure with preserved ejection fraction patients with acute heart failure and dopamine: the ROPA-DOP trial. JACC Heart Fail 6:859–870PubMed
61.
go back to reference Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr (2003) Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 284:F1115–F1119PubMed Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr (2003) Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 284:F1115–F1119PubMed
62.
go back to reference Kula AJ, Hanberg JS, Wilson FP, Brisco MA, Bellumkonda L, Jacoby D, Coca SG, Parikh CR, Tang WHW, Testani JM (2016) Influence of titration of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure. Circ Heart Fail 9:e002333PubMed Kula AJ, Hanberg JS, Wilson FP, Brisco MA, Bellumkonda L, Jacoby D, Coca SG, Parikh CR, Tang WHW, Testani JM (2016) Influence of titration of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure. Circ Heart Fail 9:e002333PubMed
63.
go back to reference Guazzi MD, Agostoni P, Perego B, Lauri G, Salvioni A, Giraldi F, Matturri M, Guazzi M, Marenzi G (1994) Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 72:534–539PubMedPubMedCentral Guazzi MD, Agostoni P, Perego B, Lauri G, Salvioni A, Giraldi F, Matturri M, Guazzi M, Marenzi G (1994) Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 72:534–539PubMedPubMedCentral
64.
go back to reference Wilson DR, Honrath U, Sonnenberg H (1983) Furosemide action on collecting ducts: effect of prostaglandin synthesis inhibition. Am J Phys 244:F666–F673 Wilson DR, Honrath U, Sonnenberg H (1983) Furosemide action on collecting ducts: effect of prostaglandin synthesis inhibition. Am J Phys 244:F666–F673
65.
go back to reference Nies AS, Gal J, Fadul S, Gerber JG (1983) Indomethacin-furosemide interaction: the importance of renal blood flow. J Pharmacol Exp Ther 226:27–32PubMed Nies AS, Gal J, Fadul S, Gerber JG (1983) Indomethacin-furosemide interaction: the importance of renal blood flow. J Pharmacol Exp Ther 226:27–32PubMed
66.
go back to reference Torsemide [package insert]. Roche Pharmaceuticals IN, NJ.; April 2003 Torsemide [package insert]. Roche Pharmaceuticals IN, NJ.; April 2003
67.
go back to reference Furosemide [package insert]. Sanofi-aventis L, Bridgewater, NJ; November 2012 Furosemide [package insert]. Sanofi-aventis L, Bridgewater, NJ; November 2012
68.
go back to reference Bumetanide [package insert]. Bedford Pharmaceuticals I, Bedford, OH.; February 2010 Bumetanide [package insert]. Bedford Pharmaceuticals I, Bedford, OH.; February 2010
69.
go back to reference Arques S, Ambrosi P (2011) Human serum albumin in the clinical syndrome of heart failure. J Card Fail 17:451–458PubMed Arques S, Ambrosi P (2011) Human serum albumin in the clinical syndrome of heart failure. J Card Fail 17:451–458PubMed
70.
go back to reference Chalasani N, Gorski JC, Horlander JC Sr, Craven R, Hoen H, Maya J, Brater DC (2001) Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 12:1010–1016PubMed Chalasani N, Gorski JC, Horlander JC Sr, Craven R, Hoen H, Maya J, Brater DC (2001) Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 12:1010–1016PubMed
71.
go back to reference Elwell RJ, Spencer AP, Eisele G (2003) Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann Pharmacother 37:695–700PubMed Elwell RJ, Spencer AP, Eisele G (2003) Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann Pharmacother 37:695–700PubMed
73.
go back to reference Grodin JL, Lala A, Stevens SR, DeVore AD, Cooper LB, AbouEzzeddine OF, Mentz RJ, Groarke JD, Joyce E, Rosenthal JL, Vader JM, Tang WH (2016) Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF. J Card Fail 22:884–890PubMedPubMedCentral Grodin JL, Lala A, Stevens SR, DeVore AD, Cooper LB, AbouEzzeddine OF, Mentz RJ, Groarke JD, Joyce E, Rosenthal JL, Vader JM, Tang WH (2016) Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF. J Card Fail 22:884–890PubMedPubMedCentral
74.
go back to reference Gupta D, Georgiopoulou VV, Kalogeropoulos AP, Dunbar SB, Reilly CM, Sands JM, Fonarow GC, Jessup M, Gheorghiade M, Yancy C, Butler J (2012) Dietary sodium intake in heart failure. Circulation. 126:479–485PubMed Gupta D, Georgiopoulou VV, Kalogeropoulos AP, Dunbar SB, Reilly CM, Sands JM, Fonarow GC, Jessup M, Gheorghiade M, Yancy C, Butler J (2012) Dietary sodium intake in heart failure. Circulation. 126:479–485PubMed
75.
go back to reference Nijst P, Verbrugge FH, Grieten L, Dupont M, Steels P, Tang WHW, Mullens W (2015) The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol 65:378–388PubMed Nijst P, Verbrugge FH, Grieten L, Dupont M, Steels P, Tang WHW, Mullens W (2015) The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol 65:378–388PubMed
76.
go back to reference Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology. 96:132–143PubMed Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology. 96:132–143PubMed
77.
go back to reference Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G, Giubilato A, Licata G (2000) Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2:305–313PubMed Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G, Giubilato A, Licata G (2000) Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2:305–313PubMed
78.
go back to reference Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G (2005) Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 45:1997–2003PubMed Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G (2005) Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 45:1997–2003PubMed
79.
go back to reference Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S (2003) Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 145:459–466PubMed Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S (2003) Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 145:459–466PubMed
80.
go back to reference Gandhi S, Mosleh W, Myers RB (2014) Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol 173:139–145PubMed Gandhi S, Mosleh W, Myers RB (2014) Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol 173:139–145PubMed
81.
go back to reference Kirchner KA, Voelker JR, Brater DC (1990) Intratubular albumin blunts the response to furosemide—a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 252:1097–1101PubMed Kirchner KA, Voelker JR, Brater DC (1990) Intratubular albumin blunts the response to furosemide—a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 252:1097–1101PubMed
82.
go back to reference Kirchner KA, Voelker JR, Brater DC (1991) Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 40:418–424PubMed Kirchner KA, Voelker JR, Brater DC (1991) Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 40:418–424PubMed
83.
go back to reference Green TP, Mirkin BL (1980) Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. Life Sci 26:623–630PubMed Green TP, Mirkin BL (1980) Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. Life Sci 26:623–630PubMed
84.
go back to reference Sabatine MS, Massachusetts General Hospital (2017) Pocket medicine: The Massachusetts General Hospital Handbook of Internal medicine. Sixth edition. Wolters Kluwer Sabatine MS, Massachusetts General Hospital (2017) Pocket medicine: The Massachusetts General Hospital Handbook of Internal medicine. Sixth edition. Wolters Kluwer
85.
go back to reference Agarwal R, Gorski JC, Sundblad K, Brater DC (2000) Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 11:1100–1105PubMed Agarwal R, Gorski JC, Sundblad K, Brater DC (2000) Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 11:1100–1105PubMed
86.
go back to reference Shem S (1979) The house of god. Bodley Head, London Shem S (1979) The house of god. Bodley Head, London
87.
go back to reference Ter Maaten JM, Rao VS, Hanberg JS, Perry Wilson F, Bellumkonda L, Assefa M, Sam Broughton J, D'Ambrosi J, Wilson Tang WH, Damman K, Voors AA, Ellison DH, Testani JM (2017) Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. Eur J Heart Fail 19:1014–1022PubMed Ter Maaten JM, Rao VS, Hanberg JS, Perry Wilson F, Bellumkonda L, Assefa M, Sam Broughton J, D'Ambrosi J, Wilson Tang WH, Damman K, Voors AA, Ellison DH, Testani JM (2017) Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. Eur J Heart Fail 19:1014–1022PubMed
88.
go back to reference Mullens W, Verbrugge FH, Nijst P, Tang WHW (2017) Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J 38:1872–1882PubMed Mullens W, Verbrugge FH, Nijst P, Tang WHW (2017) Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J 38:1872–1882PubMed
89.
go back to reference Cox ZL, Lenihan DJ (2014) Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. J Card Fail 20:611–622PubMed Cox ZL, Lenihan DJ (2014) Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. J Card Fail 20:611–622PubMed
90.
go back to reference Ellison DH (1991) The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 114:886–894PubMed Ellison DH (1991) The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 114:886–894PubMed
91.
go back to reference Stanton BA, Kaissling B (1988) Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Phys 255:F1269–F1275 Stanton BA, Kaissling B (1988) Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Phys 255:F1269–F1275
92.
go back to reference Stanton BA, Kaissling B (1989) Regulation of renal ion transport and cell growth by sodium. Am J Phys 257:F1–F10 Stanton BA, Kaissling B (1989) Regulation of renal ion transport and cell growth by sodium. Am J Phys 257:F1–F10
93.
go back to reference Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco-Bacik MA, Wilson FP, Jacoby D, Chen M, Tang WHW, Cherney DZI, Ellison DH, Testani JM (2017) Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol 28:3414–3424PubMedPubMedCentral Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco-Bacik MA, Wilson FP, Jacoby D, Chen M, Tang WHW, Cherney DZI, Ellison DH, Testani JM (2017) Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol 28:3414–3424PubMedPubMedCentral
94.
go back to reference Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O’Connor CM, Chen HH, Rouleau JL, Givertz MM, Semigran MJ, Mann D, Deswal A, Bull DA, Lewinter MM, Braunwald E (2012) Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail 18:176–182PubMedPubMedCentral Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O’Connor CM, Chen HH, Rouleau JL, Givertz MM, Semigran MJ, Mann D, Deswal A, Bull DA, Lewinter MM, Braunwald E (2012) Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail 18:176–182PubMedPubMedCentral
95.
go back to reference Felker GM, O’Connor CM, Braunwald E (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62PubMedPubMedCentral Felker GM, O’Connor CM, Braunwald E (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62PubMedPubMedCentral
96.
go back to reference Brisco-Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, Wilson FP, Testani JM (2018) Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc 7:e009149PubMedPubMedCentral Brisco-Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, Wilson FP, Testani JM (2018) Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc 7:e009149PubMedPubMedCentral
97.
go back to reference Trullas JC, Morales-Rull JL, Casado J, Freitas Ramirez A, Manzano L, Formiga F, CLOROTIC Investigators (2016) Rationale and design of the “Safety and efficacy of the combination of loop with thiazide-type diuretics in patients with decompensated heart failure (CLOROTIC) trial:” a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure. J Card Fail 22:529–536PubMed Trullas JC, Morales-Rull JL, Casado J, Freitas Ramirez A, Manzano L, Formiga F, CLOROTIC Investigators (2016) Rationale and design of the “Safety and efficacy of the combination of loop with thiazide-type diuretics in patients with decompensated heart failure (CLOROTIC) trial:” a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure. J Card Fail 22:529–536PubMed
98.
go back to reference Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296–2304PubMedPubMedCentral Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296–2304PubMedPubMedCentral
99.
go back to reference Jentzer JC, DeWald TA, Hernandez AF (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56:1527–1534PubMed Jentzer JC, DeWald TA, Hernandez AF (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56:1527–1534PubMed
100.
go back to reference Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ and Wilkoff BL. (2013) ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128:e240–e327 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ and Wilkoff BL. (2013) ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128:e240–e327
101.
go back to reference Goodman LS, Brunton LL, Chabner B, Knollmann BC (2011) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York Goodman LS, Brunton LL, Chabner B, Knollmann BC (2011) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York
102.
go back to reference Channer KS, McLean KA, Lawson-Matthew P, Richardson M (1994) Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71:146–150PubMedPubMedCentral Channer KS, McLean KA, Lawson-Matthew P, Richardson M (1994) Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71:146–150PubMedPubMedCentral
103.
go back to reference Knauf H, Mutschler E (1995) Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 26:394–400PubMed Knauf H, Mutschler E (1995) Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 26:394–400PubMed
104.
go back to reference Fliser D, Schroter M, Neubeck M, Ritz E (1994) Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 46:482–488PubMed Fliser D, Schroter M, Neubeck M, Ritz E (1994) Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 46:482–488PubMed
105.
go back to reference Sica DA (2003) Metolazone and its role in edema management. Congest Heart Fail 9:100–105PubMed Sica DA (2003) Metolazone and its role in edema management. Congest Heart Fail 9:100–105PubMed
106.
go back to reference Metolazone [package insert]; Mylan Pharmaceuticals Inc; Morgantown W. October 2004 Metolazone [package insert]; Mylan Pharmaceuticals Inc; Morgantown W. October 2004
107.
go back to reference Kissling KT, Pickworth KK (2014) Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure. Pharmacotherapy. 34:882–887PubMed Kissling KT, Pickworth KK (2014) Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure. Pharmacotherapy. 34:882–887PubMed
108.
go back to reference Ter Maaten JM, Damman K (2018) Chloride, what else? Eur J Heart Fail 20:1444–1446PubMed Ter Maaten JM, Damman K (2018) Chloride, what else? Eur J Heart Fail 20:1444–1446PubMed
109.
go back to reference Grodin JL, Testani JM, Pandey A, Sambandam K, Drazner MH, Fang JC, Tang WHW (2018) Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. Eur J Heart Fail 20:1436–1443PubMed Grodin JL, Testani JM, Pandey A, Sambandam K, Drazner MH, Fang JC, Tang WHW (2018) Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. Eur J Heart Fail 20:1436–1443PubMed
110.
go back to reference Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, Clark AL (2018) Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail 20:1426–1435PubMed Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, Clark AL (2018) Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail 20:1426–1435PubMed
111.
go back to reference Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O’Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM, Hillege HL, van Veldhuisen DJ, Voors AA and Testani JM(2016) Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail 9(8):e003109. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003109 Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O’Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM, Hillege HL, van Veldhuisen DJ, Voors AA and Testani JM(2016) Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail 9(8):e003109. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​116.​003109
112.
go back to reference Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, Grodin JL, Assefa M, Samuel Broughton J, Planavsky NJ, Ahmad T, Bellumkonda L, Tang WH, Parikh CR and Testani JM (2016) Hypochloremia and diuretic resistance in heart failure: mechanistic insights. Circ Heart Fail 9(8):e003180. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003180 Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, Grodin JL, Assefa M, Samuel Broughton J, Planavsky NJ, Ahmad T, Bellumkonda L, Tang WH, Parikh CR and Testani JM (2016) Hypochloremia and diuretic resistance in heart failure: mechanistic insights. Circ Heart Fail 9(8):e003180. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​116.​003180
113.
go back to reference Ernst ME, Moser M (2009) Use of diuretics in patients with hypertension. N Engl J Med 361:2153–2164PubMed Ernst ME, Moser M (2009) Use of diuretics in patients with hypertension. N Engl J Med 361:2153–2164PubMed
114.
go back to reference Gines P, Cardenas A, Arroyo V, Rodes J (2004) Management of cirrhosis and ascites. N Engl J Med 350:1646–1654PubMed Gines P, Cardenas A, Arroyo V, Rodes J (2004) Management of cirrhosis and ascites. N Engl J Med 350:1646–1654PubMed
115.
go back to reference European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53:397–417 European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53:397–417
116.
go back to reference Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMed Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMed
117.
go back to reference Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370–376PubMed Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370–376PubMed
118.
go back to reference Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E (2016) Rationale and design of the ATHENA-HF trial: Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure. JACC Heart Fail 4:726–735PubMedPubMedCentral Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E (2016) Rationale and design of the ATHENA-HF trial: Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure. JACC Heart Fail 4:726–735PubMedPubMedCentral
119.
go back to reference Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E, National Heart Lung and Blood Institute Heart Failure Clinical Research Network (2017) Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol 2:950–958PubMedPubMedCentral Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E, National Heart Lung and Blood Institute Heart Failure Clinical Research Network (2017) Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol 2:950–958PubMedPubMedCentral
120.
go back to reference Yang J, Young MJ (2016) Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol 27:78–85PubMed Yang J, Young MJ (2016) Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol 27:78–85PubMed
121.
go back to reference Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297:1332–1343PubMed Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297:1332–1343PubMed
122.
go back to reference Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319–1331PubMed Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319–1331PubMed
123.
go back to reference Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O’Connor CM (2003) Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 145:S51–S54PubMed Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O’Connor CM (2003) Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 145:S51–S54PubMed
124.
go back to reference Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22:423–432PubMed Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22:423–432PubMed
125.
go back to reference Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor CM (2017) Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 69:1399–1406PubMed Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor CM (2017) Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 69:1399–1406PubMed
126.
go back to reference Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE, SECRET of CHF Investigators, Coordinators, and Committee Members (2017) Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 69:1409–1419PubMed Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE, SECRET of CHF Investigators, Coordinators, and Committee Members (2017) Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 69:1409–1419PubMed
127.
go back to reference Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M (2018) Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail 20:1591–1600PubMed Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M (2018) Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail 20:1591–1600PubMed
128.
go back to reference Knauf H, Mutschler E (1997) Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 29:367–372PubMed Knauf H, Mutschler E (1997) Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 29:367–372PubMed
129.
go back to reference Verbrugge FH, Dupont M, Bertrand PB, Nijst P, Penders J, Dens J, Verhaert D, Vandervoort P, Tang WH, Mullens W (2015) Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol 70:265–273PubMed Verbrugge FH, Dupont M, Bertrand PB, Nijst P, Penders J, Dens J, Verhaert D, Vandervoort P, Tang WH, Mullens W (2015) Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol 70:265–273PubMed
Metadata
Title
Loop diuretic resistance complicating acute heart failure
Authors
Zachary L. Cox
Jeffrey M. Testani
Publication date
01-01-2020
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 1/2020
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-019-09851-9

Other articles of this Issue 1/2020

Heart Failure Reviews 1/2020 Go to the issue